Earnings trends are extremely important when evaluating stocks. At Wall St. Cheat Sheet, we view increasing earnings quarter-over-quarter as a simple way to gauge whether costs and the business model are stable. Then we like to analyze whether the company is outperforming peers in the sector. This is what we call the “E-Squared” investment analysis (‘E = Earnings Are Increasing Quarter-Over-Quarter’ + ‘E = Excellent Relative Performance Versus Peers and Sector’).
Stocks with improving earnings metrics are worthy of your extra attention. Click here to discover our CHEAT SHEET stock picks now!
Here’s your Cheat Sheet to how these 5 pharma stocks rank via earnings trends:
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ): Current Price $58.41
|Revenue ($) in millions||67.51||128.45||173.78||272.28||585.98|
|Diluted EPS ($)||-7.19||-0.23||0.83||2.67||4.79|
We note that 2010 marked a watershed in Jazz’ performance and that subsequently the company was able to dramatically improve its revenue and EPS. Smart acquisitions, of course, played a major role…
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||83.54||108.41||129.54||175.52||172.51|
|Diluted EPS ($)||0.79||0.48||0.45||0.55||3.31|
We note that EPS rocketed north in the latest quarter and keep Jazz in focus in this analysis…